Doug Langa, Novo Nordisk’s vice president for North America, told analysts on an earnings call on Nov. 2 that about 80% of people with health insurance are paying less than $25 per month for Wegovy (semaglutide), a popular weight loss medication, Reuters reports. Langa added that “most major PBMs and health plans are covering” Wegovy, which the FDA initially approved for Type 2 diabetes but expanded the indication to weight management two years ago. Novo Nordisk said that Wegovy’s sales in the U.S. increased 467% year-over-year through the third quarter even though the company reduced the supply of the drug since May. Under the pharmacy benefit, Wegovy holds covered or better status for 53% of all insured lives, according to MMIT Analytics. About 31% of covered lives have preferred access to Wegovy, often with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 11/13/23